References
- Ichihara S, Uedo N, Gotoda T. Considering the esophagogastric junction as a zone. Dig Endosc. 2017;29:3–10. doi:https://doi.org/10.1111/den.12792
- Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, et al. Esophageal and esophagogastric junction cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(7):855–83.: doi:https://doi.org/10.6004/jnccn.2019.0033
- Deans C, Yeo MSW, Soe MY, Shabbir A, Ti TK, So JBY. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35(3):617–24. doi:https://doi.org/10.1007/s00268-010-0935-0
- Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3–9. doi:https://doi.org/10.1016/j.semradonc.2012.09.008
- Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881–8. doi:https://doi.org/10.1136/gutjnl-2014-308915
- Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, Chen Z, Chen J, Zhao Y, Zhou Z, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988–2012: a single-institution, high-volume experience in China. Ann Surg. 2016;263(1):88–95.: doi:https://doi.org/10.1097/SLA.0000000000001148
- Maru GB, Gandhi K, Ramchandani A, Kumar G. The role of inflammation in skin cancer. Adv Exp Med Biol. 2014;816:437–69.
- Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102(4):599–610. doi:https://doi.org/10.1002/cpt.789
- Argiles JM, Moore-Carrasco R, Busquets S, Lopez-Soriano FJ. Catabolic mediators as targets for cancer cachexia. Drug Discov Today. 2003;8(18):838–44. doi:https://doi.org/10.1016/s1359-6446(03)02826-5
- Amin M, Edge S and Greene F: eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.
- Migita K, Matsumoto S, Wakatsuki K, Ito M, Kunishige T, Nakade H, Kitano M, Nakatani M, Sho M. The prognostic significance of inflammation-based markers in patients with recurrent gastric cancer. Surg Today. 2018;48(3):282–91. doi:https://doi.org/10.1007/s00595-017-1582-y
- Chan AW, Chan SL, Wong GL, Wong VW, Chong CC, Lai PB, Chan HL, To KF. Prognostic Nutritional Index (PNI) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection. Ann Surg Oncol. 2015;22(13):4138–48. doi:https://doi.org/10.1245/s10434-015-4516-1
- Yu W, Guo Q, Wang Z, Mao L, Wei J, Jin J, Wang J. Clinical significance of Prognostic Nutritional Index for patients with diffuse large B-cell lymphoma. Nutr Cancer. 2019;71(4):569–74. doi:https://doi.org/10.1080/01635581.2018.1540718
- Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):304–17. doi:https://doi.org/10.3322/caac.21399
- Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer. 2010;13(2):63–73. doi:https://doi.org/10.1007/s10120-010-0555-2
- Siewert JR. Adenocarcinoma of the esophago-gastric junction. Gastric Cancer. 1999;2(2):87–8. doi:https://doi.org/10.1007/s101200050028
- Matsuda T, Kurokawa Y, Yoshikawa T, Kishi K, Misawa K, Ohi M, Mine S, Hiki N, Takeuchi H. Clinicopathological characteristics and prognostic factors of patients with Siewert Type II esophagogastric junction carcinoma: a retrospective multicenter study. World J Surg. 2016;40(7):1672–9. doi:https://doi.org/10.1007/s00268-016-3451-z
- Batool S, Khan M, Akbar SA, Ashraf I. Risk factors and patterns of recurrence after curative resection in gastroesophageal junction adenocarcinoma. Pak J Med Sci. 2019;35(5):1276–83. doi:https://doi.org/10.12669/pjms.35.5.963
- Zheng Z, Yin J, Wu HW, Li J, Cai J, Qin SQ, Zhang J, Yao HW, Li JS, Zhang ZT. Explored risk factors for lymph node metastasis with Siewert II/III adenocarcinoma of the gastroesophageal junction. Anticancer Res. 2017;37(8):4605–10. doi:https://doi.org/10.21873/anticanres.11860
- Al-Sukhni E, Gabriel E, Attwood K, Kukar M, Nurkin SJ, Hochwald SN. No survival difference with neoadjuvant chemoradiotherapy compared with chemotherapy in resectable esophageal and gastroesophageal junction adenocarcinoma: results from the national cancer data base. J Am Coll Surg. 2016;223(6):784–92. doi:https://doi.org/10.1016/j.jamcollsurg.2016.09.002
- MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol. 2007;5(4):157–62. 164-166, 183,
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:https://doi.org/10.1016/j.cell.2011.02.013
- Luo Z, Zhou L, Balde AI, Li Z, He L, ZhenWei C, Zou Z, Huang S, Han S, Wei ZM, et al. Prognostic impact of preoperative prognostic nutritional index in resected advanced gastric cancer: A multicenter propensity score analysis. Eur J Surg Oncol. 2019;45(3):425–31.: doi:https://doi.org/10.1016/j.ejso.2018.09.004
- Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. Bmc Cancer. 2018;18(1):883. doi:https://doi.org/10.1186/s12885-018-4732-8
- Urabe M, Yamashita H, Watanabe T, Seto Y. Comparison of prognostic abilities among preoperative laboratory data indices in patients with resectable gastric and esophagogastric junction adenocarcinoma. World J Surg. 2018;42(1):185–94. doi:https://doi.org/10.1007/s00268-017-4146-9
- Mullen JL, Buzby GP, Matthews DC, Smale BF, Rosato EF. Reduction of operative morbidity and mortality by combined preoperative and postoperative nutritional support. Ann Surg. 1980;192:604–13.
- Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432–7. doi:https://doi.org/10.1111/j.0894-0959.2004.17603.x
- Lim WS, Roh JL, Kim SB, Choi SH, Nam SY, Kim SY. Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma. Laryngoscope. 2017;127(12):E437–E442. doi:https://doi.org/10.1002/lary.26691
- Cong L, Hu L. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2017;46:75–9. doi:https://doi.org/10.1016/j.intimp.2017.02.027
- Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, Dou R, Chen Q, Hodi FS, Choueiri TK, et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016;48(7):725–32.: doi:https://doi.org/10.1038/ng.3581
- Yoshino Y, Taguchi A, Takao M, Kashiyama T, Furusawa A, Uno M, Okada S, Kino N, Yasugi T. Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer. Int J Clin Oncol. 2019;24(4):428–36. doi:https://doi.org/10.1007/s10147-018-1374-4
- Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, Levinson KL, Tanner ER, Stone RL, Piotrowski A, et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol. 2016;140(1):76–82.: doi:https://doi.org/10.1016/j.ygyno.2015.11.013
- Kou F, Lu Z, Li J, Zhang X, Lu M, Zhou J, Wang X, Gong J, Gao J, Li J, et al. Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. Cancer Med. 2016;5(5):778–86.: doi:https://doi.org/10.1002/cam4.638
- Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Yamamoto M, Fukumoto Y, Osaki T, Ashida K, Fujiwara Y. Prognostic significance of pre- and postoperative lymphocyte counts in patients with gastric cancer. Dig Surg. 2019;36(2):137–43. doi:https://doi.org/10.1159/000486581